Skip to content
value.today
Cerenome, Inc. logo

Cerenome, Inc.

CNSY
$17 Mmarket cap on Oct 30, 2026+112.6% since Jan 2024
Compare
World rank
#24,718
Revenue
$5 M
For year ending December-2025
Net income
$-22 M
-429.8% margin
SEC filing
Employees
28
As of December 31, 2025
value.today research

Cerenome, Inc. in brief

Cerenome, Inc. is a listed company in the Biotechnology industry, based in the USA. It was founded in 1996. Its market value was $17 M on 30 October 2026, which makes it the 24,718th largest listed company in the world and the 4,184th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $22 M. It employs about 28 people. Its shares trade under the symbol CNSY (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cerenome, Inc.

Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. CNSide Diagnostics, LLC is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, our lead candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection.

Cerenome, Inc. timeline

7 events, 1996–2026
  1. 1996
  2. 🏁
    · approximate
    Founded
  3. 2000
  4. 🔔
    · approximate
    Initial public offering on Nasdaq as PSTV
  5. 2001
  6. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  7. 2005
  8. ✎
    Renamed Cytori Therapeutics, Inc.
    Formerly Macropore Inc.
  9. 2019
  10. ✎
    Renamed Plus Therapeutics, Inc.
    Formerly Cytori Therapeutics, Inc..
  11. 2024
  12. 💰
    Record revenue of $6 million
    FY2024, the highest of the 4 years on record.
  13. 2026
  14. ✎
    Renamed Cerenome, Inc.
    Formerly Plus Therapeutics, Inc..

Events of Cerenome, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$11 M$22 M$32 M$43 M2020202120222023202420252026

World rank over time

▲ up 1,898 places since 2020
2020-01-01: #26632#26,63220202021-01-01: #24416#24,41620212022-01-07: #31023#31,02320222022-12-25: #31528#31,52820222023-07-30: #32375#32,37520232024-01-05: #31632#31,63220242026-03-08: #11236#11,23620262026-10-13: #24699#24,69920262026-10-30: #24734#24,7342026

Rank in USA: #4,695 (Jan 2020) · #4,580 (Jan 2021) · #5,441 (Jan 2022) · #5,580 (Dec 2022) · #5,533 (Jul 2023) · #4,557 (Jan 2024) · #2,189 (Mar 2026) · #4,137 (Oct 2026) · #4,186 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
4.0×
Price / book
4.3×
Free cash flow yield
-122.6%
Net margin (TTM)
-621.4%
Operating margin
-293.7%
Return on equity
-652.5%
Liabilities / assets
75.6%
Net debt
$-14M
Revenue growth
-10.5%
R&D / revenue
160.8%
Revenue per employee
$186 K
Profit per employee
$-800 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $4M, net income $-13M$4MFY18Fiscal year ending Dec 2019: revenue —, net income $-11M—FY19Fiscal year ending Dec 2020: revenue —, net income $-8M—FY20Fiscal year ending Dec 2021: revenue —, net income $-13M—FY21Fiscal year ending Dec 2022: revenue —, net income $-20M—FY22Fiscal year ending Dec 2023: revenue $5M, net income $-13M$5MFY23Fiscal year ending Dec 2024: revenue $6M, net income $-13M$6MFY24Fiscal year ending Dec 2025: revenue $5M, net income $-22M$5MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$5M-10.5%$-15M$-22M-429.8%
Dec 2024$6M+18.5%$-15M$-13M-223.0%
Dec 2023$5M—$-13M$-13M-271.3%
Dec 2022——$-20M$-20M—
Dec 2021——$-12M$-13M—
Dec 2020——$-10M$-8M—
Dec 2019——$-4M$-11M—
Dec 2018$4M—$-9M$-13M-344.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-21M$0M$-21M$-0.29—
Dec 2024$-11M$0M$-11M$-2.34—
Dec 2023$-13M$0M$-13M$-4.24—
Dec 2022$-13M——$-11.58—
Dec 2021$-10M——$-1.11—
Dec 2020$-8M——$-1.86—
Dec 2019$-6M$0M$-6M$-8.27—
Dec 2018$-12M$0M$-12M$-86.98—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$4M
Net income, trailing 12 months
$-26M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-4M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-17M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $5M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-4M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-6M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-7M$1MMar ’26Three months to Jun 2026: revenue $0M, net income $-9M$0MJun ’26Three months to Sep 2026: revenue $1M, net income $-9M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-48.6% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Cerenome, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$5 M
Operating income
$-15 M
Net income
$-22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$16 M
Total liabilities
$12 M
Total equity
$4 M

As of December-2025

Top 22 institutional investors in Cerenome, Inc.#

As of Sep 30, 2026
22 institutions held 627,164 shares (about 8.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 8.2%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 22 largest institutional investors in Cerenome, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC304,7450 (0.00%)4.02%$1 MNov 13, 2026
2BlackRock, Inc.99,559+3,576 (+3.73%)1.31%$0 MNov 13, 2026
3Geode Capital Management, LLC81,743+5,588 (+7.34%)1.08%$0 MNov 6, 2026
4Vanguard Fiduciary Trust Co36,8680 (0.00%)0.49%$0 MNov 13, 2026
5Ashton Thomas Private Wealth, LLC34,3060 (0.00%)0.45%$0 MNov 3, 2026
6State Street Corp30,8530 (0.00%)0.41%$0 MNov 12, 2026
7Northern Trust Corp14,612-904 (-5.83%)0.19%$0 MNov 16, 2026
8XTX Topco Ltd11,547New0.15%$0 MNov 16, 2026
9UBS Group AG3,118+2,648 (+563.40%)0.04%$0 MNov 10, 2026
10Nuveen, LLC2,285New0.03%$0 MNov 10, 2026
11Vanguard Global Advisers, LLC2,2820 (0.00%)0.03%$0 MNov 13, 2026
12Osaic Holdings, Inc.2,0000 (0.00%)0.03%$0 MNov 12, 2026
13Tower Research Capital LLC (TRC)1,844-111 (-5.68%)0.02%$0 MNov 16, 2026
14Jpmorgan Chase & Co385New0.01%$0 MNov 12, 2026
15Royal Bank Of Canada352New0.00%$0 MNov 16, 2026
16SBI Securities Co., Ltd.2510 (0.00%)0.00%$0 MOct 22, 2026
17Morgan Stanley1850 (0.00%)0.00%$0 MNov 13, 2026
18Robinhood Markets, Inc.142—0.00%$0 MNov 18, 2026
19Barclays PLC72-24 (-25.00%)0.00%$0 MNov 6, 2026
20Wells Fargo & Company/mn6-6,150 (-99.90%)0.00%$0 MNov 16, 2026
21Caitong International Asset Management Co., Ltd5-7 (-58.33%)0.00%$0 MOct 29, 2026
22Global Retirement Partners, LLC40 (0.00%)0.00%$0 MNov 10, 2026

Mutual funds holding Cerenome, Inc.#

10 funds hold shares worth $2 M (about 5.0% of the company). Since their previous reports 4 added shares and 6 sold, selling $16 M net.
Mutual funds holding Cerenome, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.203,500$1 M2.7%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.86,245$0 M1.1%<0.01%−96%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC39,144$0 M0.52%<0.01%−95%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors23,411$0 M0.31%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,332$0 M0.14%<0.01%−95%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC9,966$0 M0.13%<0.01%−96%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,849$0 M0.04%<0.01%−96%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,518$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC135$0 M<0.01%<0.01%−94%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC20$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cerenome, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
28
since
$64 K-$4 K$0Nov 2023: bought $39 K (8 trades), sold $4 K (1 trades)Nov 23May 2024: bought $64 K (6 trades), sold $0 (0 trades)MaySep 2024: bought $53 K (6 trades), sold $0 (0 trades)SepAug 2025: bought $54 K (1 trades), sold $0 (0 trades)AugNov 2025: bought $10 K (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Cerenome, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Marc H. HedrickChief Executive Officer, DirectorOption exercise+6,387——50,870Form 4
filed Richard J. HawkinsDirectorOption exercise+921——2,450Form 4
filed An Van Es-JohanssonDirectorOption exercise+921——1,843Form 4
filed Howard ClowesDirectorOption exercise+921——2,902Form 4
filed Ronald Asbury AndrewsDirectorOption exercise+921——1,843Form 4
filed Sims Andrew John Hugh MacIntyreChief Financial OfficerOption exercise+1,533——11,474Form 4
filed Kyle GuseDirectorOption exercise+921——1,843Form 4
filed Marc H. HedrickChief Executive Officer, DirectorOption exercise+8,066——58,936Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cerenome, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
844,013
14.87 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split ; 1-for-25 reverse split ; 1-for-16.67 reverse split ; 1-for-50 reverse split ; 1-for-10 reverse split ; 15-for-1 split

Trading halts

  • 2026-11-03 15:58 UTC, code LUDP, resumed 16:03 UTC
  • 2026-11-03 15:50 UTC, code LUDP, resumed 15:55 UTC
  • 2026-11-03 15:43 UTC, code LUDP, resumed 15:48 UTC
  • 2026-11-03 15:24 UTC, code LUDP, resumed 15:38 UTC
  • 2026-04-01 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 308 shares at $1.74
  • : 28 shares at $1.76
  • : 183 shares at $1.66
  • : 4,117 shares at $1.64
  • : 1,955 shares at $1.75

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cerenome, Inc. scorecard#

Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.2×Price to book 4.2× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median4.0×Price to sales 4.0× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-122.6%Free cash flow is -122.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 3
    • ✗Revenue grew in the newest year-10.5%Revenue down 10.5% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.29 vs -2.34Diluted EPS -0.29 in fiscal 2025 against -2.34 the year before (report's currency).
    • ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$8 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-293.7%-293.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.23 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-45.99Z-score -45.99 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Cerenome, Inc.'s statements, beside the median of Biotechnology.

Cerenome, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-293.7%-60.5%
Net margin-429.8%-68.9%
Revenue growth-10.5%15.8%
Free cash flow margin-400.2%-61.5%

4of 7on the Piotroski tests of financial strength

  • Revenue fell 10.5% against the year before.
  • Net loss of $22 million, the 17th loss-making year in a row.
  • Free cash flow was negative: -$21 million.

Cerenome, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cerenome, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue5.25.84.9————3.72.74.7
Cost of revenue———————1.11.32.7
Gross profit————————0.11.9
Research and development8.4119.79.75.32.75.45.5r1216
Selling and marketing——————0.50.6r3.63.6
General and administrative129.98.5106.96.45.3r5.6r7.68.6
Operating expenses21211820129.91112r2528
Operating income−15−15−13−20−12−9.6−3.7−8.8r−21−20
Interest and finance income0.10.30.40.10.00.10.10.00.00.0
Interest expense and finance costs0.50.20.40.70.91.11.91.92.02.6
Other non-operating income (expense)−7.11.70.0−0.6−0.91.30.4−0.1r−2.0−2.3
Income before tax−22−13————————
Income tax0000000000
Income from discontinued operations—————0−7.6−3.8——
Net income attributable to shareholders−22−13−13−20−13−8.2−11−13−23−22
Earnings per share, basic-0.29-1.95-4.24-11.58r-1.11-1.86-8.27-86.98r-8.23r-1.28
Earnings per share, diluted-0.29-2.34-4.24-11.58r-1.11-1.86-8.27-86.98r-8.23r-1.28
Shares, weighted average (basic)786.63.11.8r12—————
Shares, weighted average (diluted)787.73.11.8r124.41.40.2r3.2r17
Balance sheet
Cash and cash equivalents4.30.18.618188.3185.39.613r
Short-term investments4.43.5————————
Receivables—————01.20.2r0.11.2
Inventory——————0.10.1r3.23.7
Other current assets1.71.11.33.71.30.81.00.8r1.30.9
Current assets15r5.39.822209.2209.61519
Property, plant and equipment0.30.40.91.31.51.82.22.3r3.11.2
Right-of-use (leased) assets0.10.10.20.20.30.60.8———
Goodwill0.40.40.40.40.40.40.40.4r3.93.9
Other intangible assets0.30.50.0————6.07.28.4
Total assets166.61124221223243235
Accounts payable3.39.5r4.8r8.4r2.6r0.8r0.3r0.7r1.3r1.3r
Debt due within a year——4.01.61.66.31114146.6
Current liabilities121611125.98.514181813
Long-term debt———3.85.0———011
Lease liabilities (non-current)0.00.00.10.10.30.50.6———
Total liabilities12161317119.122191924
Retained earnings−516−493−481−467−447−434−425−414−402−379
Shareholders' equity4.0−8.9−1.36.4113.01.25.21311
Total liabilities and equity166.61124221223243235
Shares outstanding5.5r5.94.4r2.2r166.73.90.3r5.8r22
Cash-flow statement
Depreciation and amortization0.40.9r0.60.60.40.40.92.02.21.2
Share-based compensation1.50.60.60.60.60.20.10.40.81.1
Cash from operating activities−21−11−13−13−10−8.4−5.9−12−18−20
Capital expenditure−0.1−0.1−0.2———−0.1−0.1−0.3−0.1
Intangible assets bought—−0.5——0−0.40——0
Cash from investing activities−0.9−4.1−0.2−0.8−0.1−0.55.6−0.1−1.4r0.1
Debt issued—————————0
Debt repaid—−4.0−1.6−1.6−0.3−5.3−3.70−4.70
Shares issued23—5.516r194.01602421
Cash from financing activities306.23.41320−0.3137.21718
Exchange-rate effect on cash————————0.00.1
Change in cash8.7−8.5−9.6−0.310−9.212−4.9−2.7r−1.8
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Cerenome, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$5.6 M
Marc H. Hedrick, M.D
Other top executives, average
$1.6 M
the CEO earned 3.4× this
$100 invested is now
$11
Cerenome, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Marc H. Hedrick, M.D$5.6 M$4.7 M$1.6 M$11
2024Marc H. Hedrick, M.D$1.3 M$1.6 M$907 K$24
2023Marc H. Hedrick, M.D$1.1 M$1.6 M$1.2 M$37

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Cerenome, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 4 · Material agreement 5 · New debt 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5

Cerenome, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Shareholder vote8-K
Auditor changed8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Cerenome, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2026$3 MPrivate placement after listing$2 to $10 million1equity, debt, optionsSEC
May 2009$4 MNo. 1$2 to $10 million41equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Cerenome, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2019–2019
Latest
—
2019-07-01
Cerenome, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2019············—
Cerenome, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Cerenome, Inc. compares in Biotechnology

  • Market cap$17 M · higher than 16% of 726
  • Revenue$5 M · higher than 36% of 647
  • Net margin-621.4% · higher than 8% of 408
  • Revenue growth-10.5% · higher than 34% of 438
  • Price / sales4.0× · lower than 67% of 339
  • Price / book4.3× · lower than 36% of 534
  • FCF yield-122.6% · higher than 8% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cerenome, Inc.🇺🇸$17 M—-621.4%-10.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cerenome, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cerenome, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cerenome, Inc.? Suggest a correction